Compare Johnson & Johnson (JNJ) vs Nextpower Inc. Common Stock (NXT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Nextpower Inc. Common Stock — how do they compare? Johnson & Johnson trades at $257.6 (market cap $611.90B), while Nextpower Inc. Common Stock trades at $81 (market cap $12.53B). The key difference: Johnson & Johnson is far larger — about 48.8× Nextpower Inc. Common Stock's market cap, and Johnson & Johnson pays a 2.11% dividend while Nextpower Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Nextpower Inc. Common Stock for 0 Days on average.
| JNJ | NXT | |
|---|---|---|
Market Cap | $611.90B | $12.53B |
Volume | 9,651,904 | 3,195,746 |
Sector | Health | Energy |
52-Week High | $278.43 | $156.40 |
52-Week Low | $186.00 | $77.93 |
Typical Hold Time | 129 Days | 0 Days |
Enterprise Value | $640.18B | $11.98B |
Dividend Yield | 2.11% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $248.61, down 5.73% over 24 hours, with a bullish technical signal supported by moving averages. The company maintains strong profitability with 67.91% gross margins and 21.48% net income margin, though valuation ratios appear elevated with a P/E of 38.59. Recent earnings show consistent beats except for Q4 2025, with Q3 2026 EPS of $2.59 exceeding expectations. Analyst consensus remains positive with a $282.53 price target, representing 13.6% upside potential from current levels.
JNJ's diversified healthcare portfolio and robust dividend history provide stability, while innovation in pharmaceuticals and medical technology drives growth. Key risks include patent expirations, regulatory challenges, and increasing debt levels. The stock offers defensive characteristics with upside potential from pipeline developments, though current valuation requires careful monitoring of execution against growth expectations.
NXT trades at $88.77, up 4.61% today, with strong analyst support (86% buy ratings) and a $144.67 consensus price target suggesting 63% upside. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results expected November 16. Revenue grew from $3.0B in 2025 to $3.6B in 2026, while maintaining robust profitability with 16.36% net margins and 27.22% ROE.
Positive outlook driven by $5.5B+ backlog and raised 2027 guidance, though rising platform investment costs and solar sector volatility present risks. Technical levels show support at $86 with resistance at $91, while valuation multiples (P/E 22.94, P/S 3.76) appear reasonable given growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Nextpower Inc. Common Stock
Nextpower Inc., formerly known as Nextracker, is a solar energy technology company that designs tracking systems, structural foundations, and electrical balance-of-system equipment for utility-scale solar power plants. The company also develops software for solar yield management and is expanding into utility-scale power conversion systems.
Read more on NXT →
